Drug intelligence / Profile preview

inetetamab + pyrotinib

Development stage: Unknown
Lead developer: CITIC Guojian Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

This combination involves **inetetamab**, an anti-HER2 antibody, and **pyrotinib**, an irreversible dual pan-ErbB receptor tyrosine kinase inhibitor. Pyrotinib targets EGFR, HER1, HER2, and HER4, inhibiting tumor cell growth by blocking key signaling pathways. The combination is used for treating HER2-positive advanced breast cancer, particularly in patients who have progressed after trastuzumab treatment.

Brand names: CipterbinAiRuiNi
Other names: pytotinib-Sun Yat-sen University-non-small cell lung cancerinetetamab and pyrotinibpyrotinib + inetetamab

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)EGFR (Epidermal growth factor receptor)ERBB4 (Erb-b2 receptor tyrosine kinase 4)

Beyond the preview

Go deeper on inetetamab + pyrotinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on inetetamab + pyrotinib.

Explore the full profile